论文部分内容阅读
目的:探讨西酞普兰合并神衰宁丸治疗脑卒中后抑郁的临床疗效。方法:将80例脑卒中后抑郁患者随机分为西酞普兰合并神衰宁丸的治疗组和西酞普兰对照组各40例,观察治疗6周。于治疗前及治疗1,2,4,6周末采用汉密顿抑郁量表(HAMD)进行抗抑郁疗效评定,用改良的爱丁堡-斯堪的纳维亚卒中量表(MESSS)进行神经功能康复评定,用治疗中出现的症状量表(TESS)评定药物不良反应。结果:HAMD和TESS评分显示,在第1和2周末治疗组和对照组区别显著(P<0.05);MESSS评分显示:在治疗6周末,治疗组(14.22±4.53)比对照组(17.38±5.10)下降显著(P<0.05)。结论:在治疗脑卒中后抑郁中,酞普兰合并神衰宁丸抗抑郁的起效更快,对神经功能的康复效果和患者的耐受性都较好。
Objective: To investigate the clinical efficacy of citalopram combined with Shenhuning Pills in the treatment of post-stroke depression. Methods: Eighty patients with post-stroke depression were randomly divided into citalopram combined with Shenfeining pill and citalopram control group, 40 cases each for 6 weeks. The antidepressant efficacy was assessed using the Hamilton Depression Rating Scale (HAMD) prior to and 1, 2, 4 and 6 weeks of treatment, and neurological functional rehabilitation using the modified Edinburgh-Scandinavian stroke scale (MESSS) The adverse reactions were evaluated by using the symptom questionnaire (TESS) in the treatment. Results: The scores of HAMD and TESS showed that there was a significant difference between the treatment group and the control group at the end of the 1st and 2nd week (P <0.05). The MESSS score showed that in the 6th week of treatment, the treatment group (14.22 ± 4.53) was 17.38 ± 5.10 ) Decreased significantly (P <0.05). CONCLUSION: In the treatment of post-stroke depression, the effect of citalopram combined with Shenhuning Pill in antidepressant is faster, and the effect on neurological rehabilitation and patient tolerance are better.